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 Abstract 
 
 Objective: To compare cognitive functions between paroxysmal and 
persistent atrial fibrillation patients without clinical stroke, in terms of 
MoCA-Ina total score and MoCA-Ina cognitive subdomains scores.
 Methods: A comparative study that compared MoCA-Ina scores between 
paroxysmal and persistent AF patients without clinical stroke, who came 
for treatment at the Cardiology Clinic Dr. Hasan Sadikin General Hospital, 
Bandung and Dustira Hospital, Cimahi from September 2018–January 
2019.
 Results: Sixty four subjects were recruited, consisted of 24 paroxysmal 
and 40 persistent AF patients. There were no difference in clinical 
characteristics between two groups, except that there were more 
subjects in the persistent AF group using anticoagulants therapy: 97.5% 
vs 62.5% (p=0.005) and more prevalence of type 2 Diabetes Mellitus in 
the paroxysmal AF group: 25% vs 2.5% (p=0.009). Cognitive impairment 
(MoCA-Ina score <25) were seen in 70.8% of paroxysmal AF group 
and 82.5% of persistent AF group (p=0.274). The mean MoCA-Ina total 
score in the paroxysmal and persistent AF groups were 21.04±4.75 vs 
20.70±4.21 (p=0.989), respectively. The median MoCA-Ina cognitive 
subdomains scores were similar for the two groups (p>0.05).
 Conclusion: There were no differences in cognitive functions between 
paroxysmal and persistent AF patients, both in terms of MoCA-Ina total 
score and MoCA-Ina cognitive subdomains scores, although in both 
groups had cognitive decline.
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Many studies have reported a significant 
association between atrial fibrillation (AF) 
and cognitive impairment and a faster 
incidence of dementia, both with and 
without the occurrence of clinical stroke 
that preceded it.1,2 The prevalence of mild 
cognitive impairment (MCI) and dementia in 
AF patients was estimated at 40%, higher than 
patients without AF.2,3 
     The mechanism of cognitive impairment in 
AF patients is mostly related to the incidence of 
cardioembolic stroke, but it is well known that 
without a stroke, AF also can cause cognitive 
impairment. Although the mechanisms 
that play a role in this case are not fully 
understood, several hypotheses have been 
stated i.e the occurrence of the silent cerebral 
infarct (SCI), cerebral hypoperfusion, vascular 
inflammation and processes involving small 
vessels (small vessel disease/SVD).3-5
     Paroxysmal and persistent AF are thought 
to have different pathophysiology of thrombus 
formation. Some experts argue that the short 
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duration of AF in paroxysmal AF patients is 
associated with smaller and newly formed 
thrombus so that early recanalization is easier. 
In the contrary, thrombus in the persistent AF 
may be larger due to the larger size of the left 
atrial auriculum. Besides that the thrombus in 
persistent AF is more organized and stronger 
so that it tends to respond less to early 
recanalization. In addition, persistent AF is also 
associated with a greater number of lesions 
than paroxysmal AF. Therefore, persistent AF 
is considered more associated with a higher 
incidence of SCI and lower cognitive function 
as compared to paroxysmal AF, even without 
previous stroke events.6 
     The MoCA-Ina test (Indonesian version 
of Montreal Cognitive Assessment) is one of 
the most frequently used and validated test 
for cognitive impairment screening.7 This 
test has a higher sensitivity and specificity in 
diagnosing mild cognitive disorders compared 
to the MMSE (Mini Mental State Examination) 
test because it covers all cognitive domains 
including executive functions.8 
     This study was aimed to compare cognitive 
function between paroxysmal and persistent 
AF patients without a clinical stroke, in 
terms of MoCA-Ina total score and MoCA-Ina 
cognitive subdomains score. 
Methods
This was a comparative study of adult 
patients (age >18 years) with paroxysmal 
and persistent AF in the cardiology clinic at 
Hasan Sadikin Hospital Bandung and Dustira 
Hospital Cimahi. Patients were excluded if 
they have had one of the following: a history of 
clinical stroke, diagnosed as Rheumatic Heart 
Disease (RHD), a history of central nervous 
system abnormalities (i.e epilepsy, Parkinson’s 
Disease, Multiple Sclerosis, moderate to severe 
head injury or brain infections), a history 
of systemic abnormalities (i.e moderate 
to severe congestive heart failure, chronic 
kidney disease, routine hemodialysis or HIV-
AIDS), using memory enhancer or other 
psychopharmaceutical drugs and had a severe 
impaired vision, hearing and motor function 
that hampered the examination. 
Ethical approval from the Health Research 
Ethics Committee of the Dr. Hasan Sadikin 
General Hospital Bandung under the ethical 
clearance No. LB.04.01/A05/EC/273/
IX/2018 was gained prior the study. Sampling 
was conducted consecutively from September 
2018 to January 2019. A comprehensive range 
of sociodemographic and clinical data were 
collected through questionnaires. Cognitive 
function data was obtained through the MoCA-
Ina test. The elegible subjects were examined 
with MoCA-Ina test after signing the informed 
consent. The MoCA-Ina test was performed by 
a trained neurology resident. MoCA-Ina total 
score and MoCA-Ina cognitive subdomains 
scores were compared between the two AF 
groups. The research datas are described 
using tables according to the variables 
identified during the study. Data was analyzed 
using SPSS version 24.0 for Windows. The 
probability value p<0.05 is considered 
statistically significant.
Results 
Sixty four subjects were recruited during the 
study’s period, consisted of 24 paroxysmal 
and 40 persistent AF patients. The comparison 
of the basic characteristics of the subjects 
between the two AF groups was shown on 
Table 1. There were no significant differences 
in demographic characteristics (age, gender 
and education level) between the two AF 
groups, so that both of groups could be 
considered homogeneous and could be 
compared. From the clinical characteristics 
there were also no statistically significant 
difference, except for the history of taking 
anticoagulant therapy and the presence of 
type 2 DM variables, where there were more 
subjects in the persistent AF group who used 
anticoagulant therapy i.e. 97.5% vs 62.5% 
(p=0.005) and more comorbidities of type 
2 DM in the paroxysmal AF group of 25% 
vs 2.5% (p=0.009). Both of these variables 
may act as confounding variables which can 
influence further statistical analysis.
The comparison of the results of the MoCA-
Ina test of the subjects between the two AF 
groups was shown on Table 2. Cognitive 
impairment (MoCA-Ina total score <25) were 
found  in paroxysmal and persistent AF groups 
(82.50% vs 70.80%, p=0.274). Similarly, the 
MoCA-Ina total score was decrease in the 
both AF groups with a mean of 21.04±4.75 
vs 20.70±4.27 (p=0.989), respectively for the 
paroxysmal and persistent AF groups.
MoCA-Ina cognitive subdomain score were 
low in both groups, especially the executive 
functioning and memory, but did not show 
a statistically significant difference. (Table 
2). Domains that were mostly disturbed in 
the paroxysmal AF group were the executive 
functioning (95.8%), memory (87.5%) and 
language (79.2%), while in the persistent 
AF group were memory (95%), executive 
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Table 1 Subject Characteristics
Variable
Group
p–valueParoxysmal AF Persistent AF
(n=24) (n=40)
Age (years) 61.32±11.45 60.12±9.59 0.655
Mean±SD
Gender 8 (33.30%) 16 (40.00%) 0.594
Male 16 (66.70%) 24 (60.00%)
Female
Education (years) 9.00 9.00 0.412
Median 6.00–16.00 6.00–16.00
Range (min–max)
Occupation 23 (95.80%) 38 (95.00%) 1.000
Active 1(4.20%) 2 (5.00%)
Not active
Duration of AF (years) 2.25 4.00 0.237
Median 0.02–20.00 0.08–21.00
Range (min–max)
Antiarrhythmic therapy 22 (91.70%) 38 (95.00% 0.627
Yes 2 (8.30%) 2 (5.00%)
No
Anticoagulant therapy 12 (50.00%) 38 (95.00%) 0.005*
Warfarin 3 (12.50%) 1 (2.50%)
NOAC 9 (37.50%) 1 (2.50%)
None
INR value 21(87.50%) 24 (60.00%) 0.207
<2 3 (12.50%) 10 (25.00%)
2–3 0 (0.00%) 6 (15.00%)
>3 0 6
Comorbidities
Hypertension 16 (66.70%) 19 (47.50%) 0.136
Type 2 DM 6 (25.00%) 1 (2.50%) 0.009*
Ischemic Heart  Disease 12 (50.00%) 12 (30.00%) 0.110
Heart Failure 12 (50.00%) 28 (70.00%) 0.110
CHA2DS2–VASc scores
Median 3.00 3.00 0.068
Range (min–max) 1.00–6.00 0.00–5.00
Note: *statistically significant, SD: standard deviation, min: minimal, max: maximal, AF: atrial fibrillation, NOAC: non 
vitamin K–antagonist oral anticoagulant, INR: International Normalized Ratio, DM: diabetes mellitus, CHA2DS2–VASc: Congestive heart failure, hypertension, Age ≥75 years, diabetes, stroke, vascular disease, Age ≥65 years, Sex category–
female
functioning (90%) and attention (82.5%). 
Orientation domain was less disturbed in both 
groups. (Table 2)
Discussion
In this study, cognitive impairment in AF 
patients was prominent, as shown by the high 
proportion of low MoCA-Ina total score and 
its cognitive subdomain score. The average 
MoCA-Ina total score in this study was lower 
than the average MoCA total score for the 
normal population with the same age (23.20 ± 
3.96).9 The proportion of cognitive impairment 
in this study were almost the same with one 
study in Indonesia, that was 86.70%, with 
mean MoCA-Ina total score was 21.77±2.87.10 
Deficits in executive functioning and memory 
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were common, as were overlapping deficits 
across multiple cognitive subdomains.11
In– this study there was no statistically 
significant difference in cognitive function 
between paroxysmal and persistent AF 
patients. This condition was also failed to be 
shown in some previous studies, although 
some clinical parameters showed differences 
between the two groups.12,13 On the contrary, 
several previous studies had found significant 
differences in cognitive function between 
patients with paroxysmal and persistent AF, 
but with different cognitive examinations.6,14,15
These different results might be causes 
Table 2 Results of MoCA–Ina Test 
Variable
Group
p–valueParoxysmal AF Persistent AF
(n=24) (n=40)
Cognitive decline based on MoCA–Ina 
score 0.274
≥25 7 (29.20%) 7 (17.50%)
<25 17 (70.80%) 33 (82.50%)
MoCA–Ina total score
Mean±SD 21.04±4.75 20.70±4.27 0.989
Attention domain
Median score 4.00 4.00 0.938
Range (min–max) 2.00–6.00 0.00–6.00
Normal 6 (25.0%) 7 (17.5%)
Abnormal 18 (75.0%) 33 (82.5%) 0.470
Memory domain
Median score 2.00 2.00 0.943
Range (min–max) 0.00–5.00 0.00–5.00
Normal 3 (12.5%) 2 (5.0%)
Abnormal 21 (87.5%) 38 (95.0%) 0.355
Language domain
Median score 4.00 4.00 0.842
Range (min–max) 1.00–6.00 2.00–6.00
Normal 5 (20.8%) 9 (22.5%)
Abnormal 19 (79.2%) 31 (77.5%) 0.876
Visuospatial domain
Median score 3.00 3.00 0.825
Range (min–max) 2.00–4.00 2.00–4.00
Normal 9 (37.5%) 15 (37.5%)
Abnormal 15 (62.5%) 25 (62.5%) 1.000
Executive functioning domain
Median score 1.00 1.00 0.611
Range (min–max) 0.00–4.00 0.00–4.00
Normal 1 (4.2%) 4 (10.0%)
Abnormal 23 (95.8%) 36 (90.0%) 0.642
Orientation domain
Median score 6.00 6.00 0.993
Range (min–max) 3.00–6.00 2.00–6.00
Normal 16(66.7%) 27(67.5%)
Abnormal 8(33.3%) 13(32.5%) 0.945
Note: SD: Standard Deviation, min: minimal, max: maximal, MoCA–Ina: Indonesian version of Montreal Cognitive 
Assesment, AF: Atrial Fibrillation
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by several things i.e differences in the 
characteristics of the subjects, differences 
in the methodology, differences in cognitive 
function tests and differences in other 
comorbidities that can also affect cognitive 
function. In this study, between the two AF 
groups there were significant differences in 
two variables of clinical characteristics i.e the 
anticoagulant therapy and comorbidity of type 
2 DM (Table 1). These two variables in the 
paroxysmal AF group could cause more severe 
cognitive impairment than they should be.
The majority of subjects in this study, 
especially the paroxysmal AF group, received 
less anticoagulant therapy and did not achieved 
therapeutic INR range so that they were at 
high risk for thromboembolism, including 
microemboli which could cause microinfarct 
in the brain, leading a cognitive impairment. 
This was in accordance with several previous 
studies, who stated that anticoagulant therapy 
and therapeutic INR  were important to prevent 
embolism.16,17 Futhermore, there was more 
comorbidity of type 2 DM in the paroxysmal 
AF group, where as it was known that AF 
patients who had type 2 DM comorbidity 
would have a higher tendency for cerebral 
ischemic which of course will have a negative 
impact on cognitive function, as showed in 
some previous studies.18,19
However, subsequent analysis of these 
two variables, both with multiple regressions 
(with adjusted) and other subanalysis, 
showed that there were no significant effects 
of these two variables on the analysis of the 
comparison of MoCA-Ina scores between the 
paroxysmal and persistent AF groups, even 
though the characteristics of the two variables 
significantly different between the two groups. 
One reason that can be considered is whether 
there are differences in the characteristics 
of anticoagulant therapy and comorbidity 
of type 2 DM variables which have not been 
further evaluated in this study such as the 
small number of samples with type 2 DM 
comorbidity, the effect of type 2 DM treatment 
and glycemic control, duration of drug use, 
compliance, the type of drug, the effectiveness 
and drug interactions that might be different 
in the two AF groups thus affecting the results 
of this study.
The results of several additional analyses 
above, most likely indeed illustrate that in 
this study most patients in the paroxysmal 
AF group had cognitive decline as well as in 
the persistent AF group. Although not in line 
with the differences in the pathophysiology 
of thrombus formation described previously, 
this is still possible because both groups have 
a median CHA2DS2-VASc score =3 which means that they have a high risk of thromboembolism/ 
microembolism as well as the risk of SCI. 
Several studies linking CHA2DS2-VASc scores with cognitive impairment, reported a 2-fold 
increased risk of cognitive decline in patients 
with a score of ≥3.2,11 Nowadays screening 
and administration of anticoagulants in AF 
patients is not based on AF type but based on 
thromboembolic risk, one of which is using 
the CHA2DS2-VASc score.20 Many guidelines have recommended the administration of 
anticoagulants for paroxysmal AF patients 
with the same criteria as those applied to 
persistent AF patients.21
By assuming that cognitive impairment is 
a predictor of SCI in paroxysmal AF patients, 
it is expected that different approaches can be 
given for the management of paroxysmal AF 
patients, such as periodic cognitive function 
screening, neuroimaging examination to see 
lesions of SCI and most importantly, early 
anticoagulant therapy can be given to the 
patients with impaired cognitive function 
even though the CHA2DS2-VASc score <2.In addition to SCI, several other mechanisms 
need to be considered as the pathophysiology 
that causes cognitive impairment in AF 
patients, such as cerebral hypoperfusion and 
vascular inflammation.4 However, there has 
been no studies that specifically analyzed 
them in paroxysmal and persistent AF 
patients. Furthermore, this study also did not 
collect and analyze variables that might be 
different in the two AF groups based on the 
above mechanisms, such as measurement of 
cardiac output or cardiac index which could 
be indicators of cerebral hypoperfusion or 
measurement of inflammatory mediators 
that could support the presence of vascular 
inflammation. 
In conclusion, cognitive function in 
paroxysmal AF patients did not show 
differences with persistent AF patients in 
terms of MoCA-Ina total score and MoCA-
Ina cognitive subdomain score. Both AF 
groups had lower cognitive function than the 
general population without AF. Therefore, 
it is important to screen cognitive function 
in all AF patients using the MoCA-Ina test, 
besides that it is necessary to consider giving 
anticoagulants for the prevention of stroke or 
SCI in AF patients.
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